? RECRUITMENT, INTERVENTION AND SURVEY SHARED RESOURCE (RISSR) The RISSR was established in 2003, as the Behavioral Measurement Shared Resource (BMSR), to provide a mechanism for supporting behavioral, epidemiological and clinical research within the broader research goals of the OSUCCC. Renamed in 2019, the RISSR provides essential services to support non-interventional studies (observational, epidemiologic) as well as non-therapeutic intervention studies. Thus, the RISSR is a niche service for population scientists in CC and MCC providing efficient and high quality services for investigators to conduct population science research. RISSR also works with the BSSR to support the Total Cancer Care (TCC) project accruals, and translational research involving human data collection and interventions for all 5 research programs. For the next funding period, the RISSR specific aims are to: 1) provide expertise in research design, the selection and/or development of surveys and study measures, including patient-reported outcomes; 2) assist investigators with participant recruitment, accrual goals, and retention to ensure the inclusion of research participants that are representative of the target population(s); and 3) provide investigators with expertise and services in the collection and management of quantitative and qualitative research data, and population-based data retrieval for grant applications and registry studies. Collected data are managed for seamless transfer to the BSR for data analysis. Over the current funding cycle, the major changes to the RISSR were greater adoption of electronic data collection for the majority of OSUCCC studies, using text messaging with participants for more flexible communication, data collection and study conduct; increased use of mobile health interventions; and providing support for more program projects and large multi-heath center/ multi-state research projects. During the current funding cycle, RISSR has supported 35 principal investigators (54% OSUCCC members) and contributed to 71 publications (1 >10 impact factor) and 9 NCI grants including 1 K01, 1 K07, 1 K12, 1 P01, 2 P50s, 2 R01s, and 1 R37. The RISSR will directly support the OSUCCC priority for immune-oncology and cancer prevention and control. The RISSR will expand its staff, instrumentation and services before capacity is reached. In the next funding cycle, the RISSR will: 1) further develop and customize survey and data collection methods; 2) expand and support participant recruitment registries for rapid accrual for interventional and epidemiological studies; 3) expand the provision of smart phones to study participants to reduce disparities in participant recruitment and participation; and 4) develop greater linkages with the BISR to share computer platforms and expertise related to clinical informatics, eHealth interventions using the electronic health record, and health services research. The RISSR will also work with the BSR and BISR as part of the Biomedical Informatics Coordinating Center (BMICC) Working Group to establish national data coordinating centers at the OSUCCC on cancer-related topics. The annual budget of the RISSR is $1,631,722, yet the CCSG request is $92,102 (5.6%) reflecting strong institutional support and a robust chargeback system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090018
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications